SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
13F holders, Q2 2024
Institutional positions in SAB Biotherapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −2 vs. Q1 2024
- Shares held
- 3.13M
- −212.5K (−6.4%) vs. Q1 2024
- Total value
- $9.69M
- −$5.47M (−36.1%) vs. Q1 2024
- New holders
- 2
- 5 more added
- Sold out
- 4
- 4 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SABS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 87 | $266.8M |
| Q1 2026 | 76 | $265.0M |
| Q4 2025 | 48 | $135.9M |
| Q3 2025 | 34 | $56.3M |
| Q2 2025 | 25 | $3.37M |
| Q1 2025 | 26 | $2.99M |
| Q4 2024 | 25 | $10.1M |
| Q3 2024 | 25 | $8.48M |
| Q2 2024 | 22 | $9.69M |
| Q1 2024 | 24 | $15.2M |
| Q4 2023 | 42 | $24.5M |
| Q3 2023 | 34 | $2.41M |
| Q2 2023 | 38 | $3.28M |
| Q1 2023 | 39 | $1.71M |
| Q4 2022 | 38 | $2.42M |
| Q3 2022 | 40 | $2.32M |
| Q2 2022 | 37 | $4.45M |
| Q1 2022 | 27 | $6.71M |
| Q4 2021 | 34 | $25.4M |
| Q3 2021 | 1 | $605.0K |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding SAB Biotherapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BVF Inc | 917,826 | $2.85M | 0.08% | 00.0% | Unchanged |
| RTW Investments, LP | 766,946 | $2.38M | 0.04% | −150,881−16.4% | Reduced |
| Marshall Wace, LLP | 459,168 | $1.42M | 0.00% | 00.0% | Unchanged |
| Sessa Capital IM, L.P. | 458,457 | $1.42M | 0.06% | 00.0% | Unchanged |
| Vanguard Group Inc | 276,336 | $856.6K | 0.00% | +100,002+56.7% | Added |
| Geode Capital Management, LLC | 59,415 | $184.2K | 0.00% | −4,051−6.4% | Reduced |
| Millennium Management LLC | 52,784 | $163.6K | 0.00% | −1,266−2.3% | Reduced |
| Pathstone Holdings, LLC | 50,650 | $157.0K | 0.00% | 00.0% | Unchanged |
| First Manhattan Co | 24,577 | $76.2K | 0.00% | 00.0% | Unchanged |
| First PREMIER Bank | 19,386 | $60.0K | 0.02% | +19,386 | New |
| Institutional & Family Asset Management, LLC | 19,201 | $59.5K | 0.01% | 00.0% | Unchanged |
| BlackRock Inc. | 13,752 | $42.6K | 0.00% | +7,413+116.9% | Added |
| Advisor Group Holdings, Inc. | 4,534 | $14.1K | 0.00% | +10+0.2% | Added |
| Tower Research Capital LLC (TRC) | 2,393 | $7.42K | 0.00% | +957+66.6% | Added |
| Morgan Stanley | 699 | $2.17K | 0.00% | −500−41.7% | Reduced |
| Princeton Global Asset Management LLC | 500 | $1.55K | 0.00% | 00.0% | Unchanged |
| Gs Investments, Inc. | 200 | $620 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 165 | $511 | 0.00% | +165 | New |
| JPMorgan Chase & Co | 106 | $329 | 0.00% | +2+1.9% | Added |
| Harbour Investments, Inc. | 50 | $155 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 6 | $19 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 6 | $0 | 0.00% | 00.0% | Unchanged |
| Commodore Capital LP | 0 | $0 | 0.00% | −183,174−100.0% | Sold out |
| Spectrum Wealth Counsel, LLC | 0 | $0 | 0.00% | −503−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −61−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −14−100.0% | Sold out |